Clinical trials: Covid19 Vaccine
Covid19
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above
The aim of the clinical study is to study the safety, reactogenicity and immunogenicity indicators of the EpiVacCorona vaccine, with the involvement of volunteers aged 60 years and above.
- Trial name
- NCT05021016
- Testing
- EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
- Where
- Russia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
COVID-19
Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)
This is a first in human, phase I, open-label, dose-escalation study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in healthy adults.
- Trial name
- NCT05113849
- Testing
- IN-B009 (Low-dose), IN-B009 (High-dose)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
SARS-CoV-2
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
This clinical trial will evaluate the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2(COVID-19) in healthy volunteers.
- Trial name
- NCT04673149
- Testing
- GLS-5310
- Where
- South Korea
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Covid19, SARS-CoV Infection
Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers
- Conditions
- Covid19, SARS-CoV Infection, Vaccine Adverse Reaction
- Trial name
- NCT04691908
- Testing
- QazCovid-in®-vaccine against COVID-19
- Where
- Kazakhstan
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Research Institute for Biological Safety Problems
Vaccine Reaction, Oncology
FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination
It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of…
- Trial name
- fdg (NCT05270967)
- Testing
- F-18 FDG PET/CT imaging, Pfizer/biontech mRNA vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Kocaeli University
Virus Diseases, Pneumonia
Universal Anti-Viral Vaccine for Healthy Elderly Adults
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection…
- Conditions
- Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia
- Trial name
- ALLOPRIME (NCT04441047)
- Testing
- AlloStim
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mirror Biologics, Inc.
COVID-19 Vaccines
The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes
During the study, members of different online and offline communities will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either…
- Trial name
- NCT04832932
- Testing
- COVID-19 vaccines
- Where
- 5 sites in United States, Georgia and 2 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Mebo Research, Inc.
Coronavirus Disease 2019
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
Popular topic：Clinical study on the immune program of recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell). Research purpose:Main purpose: To evaluate the immunogenicity of recombinant novel coronavirus vaccine (CHO cells)…
- Trial name
- NCT05128643
- Testing
- Recombinant novel coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19 VACCINE, Covid19
Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina
Randomized, open, multicenter, collaborative and adaptive non-inferiority trial to evaluate the immunogenicity and reactogenicity of the heterologous vaccination schedules made up of the combination of vaccines available in…
- Trial name
- ECEHeVac (NCT04988048)
- Testing
- COVID-19 vaccines
- Where
- 4 sites in Argentina
- Volunteers
- 1,760 people, healthy volunteers welcome
- Sponsor
- Ministry of Public Health, Argentina
COVID-19 Immunisation, Influenza Vaccine
Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine.
- Trial name
- NCT06646406
- Testing
- Patient letter and clinician communication
- Where
- 2 sites in United States
- Volunteers
- 114,165 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Old Age; Debility, Vaccine Hesitancy
COVID-19 Vaccination Willingness in Older Adults Based on Self-determination Theory
Introduction: The COVID-19 vaccine is an effective measure for preventing and controlling COVID-19 epidemics, and the World Health Organization lists older adults as a high-priority group for COVID-19 vaccination.
- Conditions
- Old Age; Debility, Vaccine Hesitancy, Vaccine Refusal
- Trial name
- CVWIOABOSDT (NCT06575114)
- Testing
- Self-determination theory-based health education measures
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Jing-Shan Deng
SARS-CoV-2 Infection
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.
- Trial name
- CoVPN 3006 (NCT04811664)
- Testing
- Moderna COVID-19 Vaccine
- Where
- 51 sites in United States
- Volunteers
- 1,923 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults
In this multi-center phase II clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine MVA-SARS-2-S, or placebo.
- Trial name
- NCT05950776
- Testing
- MVA-SARS-2-S
- Volunteers
- healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
COVID -19, SARS CoV 2 Infection
Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that emerged in the human population in Wuhan City, Hubei Province, China in December 2019.
- Trial name
- NCT07408297
- Testing
- Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine
- Where
- Kenya
- Volunteers
- 1,919 people, healthy volunteers welcome
- Sponsor
- Victoria Biomedical Research Institute
Beliefs
Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine
This study seeks to assess the efficacy of educational messages to correct misperceptions. People hold a number of misperceptions that are relevant to public health, including misperceptions regarding COVID vaccines.
- Trial name
- NCT05085613
- Testing
- Corrective message framing and humor
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Inflammatory Bowel Diseases
Effectiveness and Safety of COVID-19 Vaccine in Patients With IBD Treated With Immunomodulatory or Biological Drugs (ESCAPE-IBD)
The COVID-19 pandemic has led to initial concerns for patients with Inflammatory Bowel Disease treated with immunosuppressive drugs, as they could be theoretically exposed to a higher risk of SARS-CoV-2 infection and/or severe…
- Trial name
- ESCAPE-IBD (NCT04769258)
- Testing
- Pfizer Comirnaty vaccine
- Volunteers
- 1,380 people
- Sponsor
- Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
COVID-19 Vaccines
A Study of COVID-19 Vaccine(s) in Children and Adults
The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age…
- Trial name
- NCT07798648
- Testing
- BNT162b2
- Where
- 14 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Vaccine Reaction, COVID-19
Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children
COVID-19 vaccine response data in children 5 to 11 years old remain scarce. Our understanding of the safety and immune responses including humoral and cellular responses generated in children remains limited.
- Conditions
- Vaccine Reaction, COVID-19, Children, Only
- Trial name
- NCT05329064
- Testing
- BNT162b2 Pfizer-BioNTech/Comirnaty
- Where
- Singapore
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- KK Women's and Children's Hospital
COVID-19
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
The purpose of this study is to assess the immunogenicity of nationally available pre-defined homologous booster vaccination of a SARS-CoV-2 WHO EUA qualified vaccination in adults aged 18 years and older
- Trial name
- NCT05710289
- Testing
- Immune Responses
- Volunteers
- healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.